Focus: Multi-target T cell engagers (TCEs) that redirect T cells against intracellular cancer antigens presented as peptide-MHC (pMHC) complexes on solid tumors

Problem: Solid tumors evade single-target immunotherapies through antigen escape and tumor heterogeneity; conventional biologics can only reach surface proteins (~10% of the proteome), missing the vast majority of cancer-driving targets

Approach: Proprietary TCR specificity engineering and stabilization technologies enabling a single T cell engager to recognize multiple tumor-specific pMHC targets simultaneously; designed to overcome antigen escape and heterogeneity in one drug

Lead Asset: DBXO-1 — multi-target pMHC-directed T cell engager for solid tumors (preclinical; AACR 2026 data presentation)

Backing: Funding undisclosed; LabCentral Golden Tickets from both Servier and Bristol Myers Squibb; operating out of LabCentral Kendall Square

Leadership: Jack Silberstein (Founder, CEO) — Stanford Ph.D. in protein engineering (Cochran Lab); Stanford Interdisciplinary Graduate Fellow

Deck Bio is building T cell engagers that can simultaneously recognize multiple intracellular cancer antigens — a deliberate design choice aimed at the two biggest failure modes in solid tumor immunotherapy. Most cancer-driving proteins sit inside the cell, invisible to conventional antibodies. Tumor cells present fragments of these proteins on their surface as peptide-MHC (pMHC) complexes, and TCR-based T cell engagers can be engineered to redirect T cells against them. The problem: every pMHC-targeted TCE in the clinic hits a single antigen, and tumors routinely escape by downregulating that target.

Deck Bio’s platform engineers TCR-based binders with multi-target specificity — meaning one drug can engage T cells against several tumor-specific pMHC targets at once. This directly addresses antigen escape and tumor heterogeneity, the two mechanisms that have stalled most solid tumor TCE programs. The company launched publicly in April 2026, with preclinical data for lead candidate DBXO-1 debuting at the AACR Annual Meeting.

DBXO-1 — Multi-Target pMHC T Cell Engager in Solid Tumors

First-in-class multi-target pMHC-directed T cell engager designed to simultaneously engage multiple tumor-specific intracellular antigens. Preclinical data to be presented at AACR Annual Meeting 2026. Platform leverages proprietary TCR specificity engineering and stabilization technologies to address tumor heterogeneity, antigen escape, and treatment resistance across multiple solid tumor indications.

Company	Approach	Stage	Differentiator
Deck Bio	Multi-target pMHC TCE	Preclinical	Simultaneous multi-pMHC recognition from single binder; directly addresses antigen escape
Immunocore	ImmTAC soluble TCR-CD3 bispecific	Commercial / Phase 3	KIMMTRAK approved (uveal melanoma); brenetafusp (PRAME) in Phase 3 cutaneous melanoma; only OS-positive TCR bispecific in solid tumors
CDR-Life	M-gager® TCR-mimetic TCE	Phase 1	CDR404 targets MAGE-A4 pMHC (HLA-A*02:01); 6 candidates generated; 2 in patients
Enara Bio	Dark Antigen® pMHC TCE	Preclinical	ENA101 targets DARKFOX (novel antigen from genomic dark matter); AACR 2026 oral; picomolar affinity
Adaptimmune	TCR-T cell therapy (not TCE)	Commercial	Tecelra (afami-cel) approved for synovial sarcoma; MAGE-A4 TCR-T; autologous, not off-the-shelf
Amgen (tarlatamab)	BiTE — surface antigen (DLL3×CD3)	Commercial	IMDELLTRA approved for SCLC; targets surface protein, not intracellular pMHC — limited target repertoire

The global T cell engager market reached approximately $7.7 billion in 2025 and is projected to exceed $32 billion by 2035 — but solid tumors remain the frontier. Only two TCEs have FDA approval for solid indications (tebentafusp in uveal melanoma, tarlatamab in SCLC), both targeting a single antigen. Platforms that can overcome solid tumor heterogeneity without requiring cocktails of separate drugs are where the next wave of pharma licensing deals will concentrate — and Deck Bio’s multi-target architecture is purpose-built for that thesis.

The unlock: T cell engagers have proven they can generate overall survival benefit in solid tumors — tebentafusp’s Phase 3 data in uveal melanoma settled that question. But single-target approaches hit a ceiling: tumors are heterogeneous and evolve under selective pressure. If a single drug can engage T cells against multiple intracellular cancer targets simultaneously, it fundamentally changes the durability equation for solid tumor immunotherapy. That’s not a better version of what exists — it’s a different category of drug.

For investors: Deck Bio is pre-seed or seed-stage with AACR 2026 data as the first public proof point. The risk is binary and early: does multi-target pMHC recognition translate to potent, selective tumor killing in preclinical models without unacceptable cross-reactivity? If the data are clean, the company will be well-positioned to raise a Series A into a market where Immunocore’s $3B+ market cap has validated the pMHC-targeting thesis and pharma BD teams are actively scouting next-generation platforms.

For pharma BD: Any organization with a solid tumor immunotherapy pipeline should be tracking Deck Bio’s AACR data. Multi-target pMHC engagement could become the backbone of combination strategies in tumors where single-antigen approaches are hitting resistance ceilings. The time to build a relationship is before the data generate competitive interest — not after.

🌐 Website

Multi-Target pMHC Recognition: Proprietary TCR specificity engineering enables a single T cell engager binder to recognize multiple tumor-specific peptide-MHC complexes — targeting intracellular cancer antigens that conventional antibodies cannot reach.

TCR Stabilization Platform: Engineered soluble TCR constructs with enhanced stability and manufacturability, designed for off-the-shelf subcutaneous or IV delivery without the cell manufacturing complexity of TCR-T therapies.